GLP-1 Collective

Policy Tracker · Patient Lens · September 16, 2026

Five new GLP-1 trials open doors for kidney, heart and Type 1 patients

None of these trials have started dosing yet, but they could widen who qualifies for GLP-1 treatment beyond typical obesity and Type 2 diabetes cases.

Key details

  • A Canadian trial will test oral semaglutide to prevent diabetes after a kidney transplant.
  • A Phase 3 trial is recruiting people with obesity and heart failure with preserved or mildly reduced ejection fraction.
  • A Phase 2 study will test tirzepatide in people with Type 1 diabetes, a group these drugs are not approved for.
  • Novo Nordisk and Alnylam each opened early trials of experimental obesity drugs, one of them combined with tirzepatide.

5 developments affecting GLP-1 access were tracked on Tuesday, September 15, 2026, across 1 category. Each entry links to the full record.

## Research and trials

**[Novo Nordisk's new obesity drug takes on Wegovy in 2026 trial](/fda/clinical-trial-nct07639021)**. Novo Nordisk is recruiting 230 people with obesity for a Phase 2 trial testing a new experimental drug called NNC0662-0419.

**[Semaglutide pill being tested to prevent diabetes after kidney](/fda/clinical-trial-nct06913023)**. A Canadian clinical trial is testing whether oral semaglutide can prevent diabetes in kidney transplant patients, it has not started yet.

**[First tirzepatide trial for Type 1 diabetes opens](/fda/clinical-trial-nct06820281)**. A Phase 2 study will test tirzepatide in people with Type 1 diabetes, but it hasn't started yet.

**[New obesity drug tested alongside tirzepatide in clinical trial](/fda/clinical-trial-nct07463846)**. Alnylam is testing a new obesity drug called ALN-2232, alone and combined with tirzepatide, in a clinical trial now recruiting.

**[New GLP-1 drug tested for heart failure and obesity](/fda/clinical-trial-nct07037459)**. A large Phase 3 trial is now recruiting patients with obesity and certain types of heart failure to test a new GLP-1-like drug called maritide.

By Amanda Bonello

Originally published by Patient Lens on GLP-1 Laws, operated by GLP-1 Studio LLC — a for-profit company founded by the Collective's Executive Director. Republished here in full, with permission, at no cost. The Collective pays nothing for it and receives no payment for publishing it. How this works.